Acute myeloid leukemia or myelodysplastic syndrome of high risk group research hub

A study testing increasing amounts (doses) of CC-91633 to find out what dose can be tolerated without serious side effects in patients with acute myeloid leukemia (AML) that has come back after treatment or cannot be cured or treated by any other known therapies, also called relapsed or refractory AML (R/R AML) and in patients with relapsed or refractory higher-risk myeloid dysplastic syndrome (R/R HR-MDS).

This study is testing a new medicine, CC-91633, for people with specific types of blood cancers: acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS). We want to find the safest dose of this new medicine for those whose cancer has returned or isn't responding to other treatments.